project id: TCGA-ESCA; case submitter id: TCGA-JY-A93D; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.68; rna integrity number: 7.8; age at index: 51; days to birth: -18813; days to death: 960; ethnicity: not reported; gender: male; race: white; vital status: Dead; year of birth: 1961; age at diagnosis: 18813; ajcc pathologic m: M0; ajcc pathologic n: N3; ajcc pathologic stage: Stage IIIC; ajcc pathologic t: T2; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 769.0; icd 10 code: C15.5; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lower third of esophagus; synchronous malignancy: No; tissue or organ of origin: Lower third of esophagus; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: yes; alcohol history: Yes; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 573; days to sample procurement: 0; initial weight: 90.0; portion submitter id: TCGA-JY-A93D-01A-11; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 10.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0;